- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03101501
A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Minnesota
-
Bloomington, Minnesota, United States, 55420
- Chu Vision Institue
-
-
Texas
-
Dallas, Texas, United States, 75243
- Key-Whitman Eye Center
-
San Antonio, Texas, United States, 78229
- Parkhurst NuVision
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
4.2.1 Presbyopic patients 41-65 years of age.
4.2.2 Pseudophakic patients at least 50 years of age.
4.2.3 Patients require a near reading add from +1.50 to +2.50 D in the non-dominant eye.
4.2.4 Patients have a photopic pupil size of at least 3.0 mm in the non-dominant eye.
4.2.5 Patients have a corneal thickness greater than or equal to 500 microns in the non-dominant eye.
4.2.6 Patients have corrected distance and near visual acuity of 20/25 or better in each eye.
4.2.7 Patients have distance corrected near visual acuity of 20/40 or worse in each eye.
4.2.8 Patients have no more than a 0.75 D difference at preop between MRSE and cycloplegic refraction spherical equivalent determined at the spectacle plane of each eye.
4.2.9 Patients have targeted MRSE from -0.5 to +1.0 D in the non-dominant eye, with no more than 0.75 D of manifest cylinder with or without LASIK.
4.2.10 Patients are willing and able to sign a written Informed Consent Form prior to any study-specific procedures.
4.2.11 Pseudophakic patients must be at least 3 months after cataract surgery.
4.2.12 Pseudophakic patients must have clear posterior capsule, open posterior capsule (post YAG Capsulotomy), or posterior capsule opacification that is not clinically significant at the opinion of the investigator.
4.2.13 Patients are willing and able to return for scheduled follow-up examinations for 24 months after the corneal inlay surgery.
Exclusion Criteria
4.3.1 Patients with prior corneal surgery including LASIK surgery in the non-dominant eye. (Not including Astigmatic Keratotomy or Limbal Relaxing Incisions)
4.3.2 Patients with clinically significant dry eye (i.e., significant diffuse punctate staining with fluorescein and a tear breakup time less than 8 s) in either eye.
4.3.3 Patients with a planned corneal residual bed thickness that is less than 300 microns (corneal thickness - (intended ablation depth + intended flap thickness)).
4.3.4 Patients with clinically significant macular pathology based on dilated fundus exam and/or optical coherence tomography (OCT) image.
4.3.5 Patients who would be co-managed by an ophthalmologist or optometrist who is not an approved sub-investigator.
4.3.6 Patients with ocular pathology or disease (including pupil pathology such as fixated pupils) that might confound the outcome or increase the risk of adverse event in the investigator's opinion.
4.3.7 Patients taking systemic or topical medications that might confound the outcome or increase the risk of adverse event. Patients taking isotretinoin or amiodarone hydrochloride and any other medication that affects the tear film or accommodation, including but not limited to, mydriatic, cycloplegic and mitotic agents, or any other medications in the investigator's opinion.
4.3.8 Patients with known sensitivity to any planned study medications.
4.3.9 Patients with residual, recurrent, active or uncontrolled eyelid disease.
4.3.10 Patients with significant corneal asymmetry or irregular topography.
4.3.11 Patients with clinically significant anterior segment pathology.
4.3.12 Patients with any corneal abnormality, including but not limited to, slit lamp findings for corneal staining Grade 3 or higher, recurrent corneal erosion or severe basement membrane disease, and pterygium extending onto the cornea.
4.3.13 Patients with ophthalmoscopic/topographic signs of keratoconus or those who are keratoconus suspect.
4.3.14 Patients with history of Herpes zoster or Herpes simplex keratitis.
4.3.15 Pseudophakic patients that have anterior chamber IOLs, multifocal IOLs, or extended range of vision IOLs in either eye.
4.3.16 Patients with any progressive retinal disease or subjects with a history or evidence of retinal vascular occlusion and/or hypercoagulability, because of the risks associated with high pressures during suction application.
4.3.17 Patients with known history of steroid-responsive intraocular pressure increases, glaucoma, preoperative IOP > 21 mm Hg, or are otherwise suspected of having glaucoma.
4.3.18 Patients with amblyopia or strabismus or those who are at risk for developing strabismus postoperatively as determined by corneal light reflex and cover-uncover testing.
4.3.19 Patients with diabetic retinopathy, collagen, vascular, diagnosed autoimmune disease (e.g., lupus, rheumatoid arthritis, fibromylagia), immunodeficiency (e.g., HIV), connective tissue disease, or clinically significant atopic syndrome.
4.3.20 Patients on chronic systemic corticosteroid or other immunosuppressive therapy that may affect wound healing at the opinion of the investigator.
4.3.21 Patients with any type of active cancer (ophthalmic or non-ophthalmic).
4.3.22 Patients with uncontrolled infections of any kind.
4.3.23 Patients who are pregnant, lactating, of child-bearing potential and not practicing a medically approved method of birth control, or planning to become pregnant during the course of the trial, and patients with other conditions associated with fluctuation of hormones that could lead to refractive changes.
4.3.24 Patients who actively participate in contact sports (i.e., boxing, martial arts) where impacts to the face and eye are a normal occurrence.
4.3.25 Patients participating in any other ophthalmic or non-ophthalmic drug/device clinical trials during the time of this clinical investigation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MMC for fibrosis prevention
no intervention is required after procedure is performed
|
Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uncorrected Visual Acuity
Time Frame: 24 months
|
After the inlay procedure, patients will attain functional near visual acuity in the inlay eye and functional distance acuity binocularly.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Corneal Reaction
Time Frame: 24 months
|
Patients treated with low dose mitomycin C will have minimal levels of corneal reaction.
|
24 months
|
Endothelial Cell Count (measured by Konan Specular Microscope)
Time Frame: 24 months
|
Patients treated with low dose mitomycin C will not lose more than 10% of their endothelial cell count from the preoperative measurement
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffrey Whitman, M.D., Key-Whitman Eye Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P17-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
Lee, Steven, M.D.CompletedMyopia, | Hyperopia, | Astigmatism, | Presbyopia, | Eye Strain,
-
Allotex, Inc.RecruitingPresbyopiaCzechia, Ireland, Turkey, United Kingdom
-
Coopervision, Inc.Centre for Ocular Research & Education, CanadaRecruitingPresbyopiaUnited States, Canada
-
Optall VisionRecruiting
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncCompleted
-
Allotex, Inc.TerminatedPresbyopiaBelgium, Ireland, United Kingdom
-
Coopervision, Inc.CORECompletedPresbyopiaUnited States, Canada
Clinical Trials on Mitomycin c
-
Guy's and St Thomas' NHS Foundation TrustUnknownPrimary Open Angle GlaucomaUnited Kingdom
-
University of California, San DiegoCompletedOpen Angle Glaucoma
-
Medical Enterprises Ltd.TerminatedUrinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedSolid NeoplasmUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Van Andel Research InstituteWithdrawnPancreatic CancerUnited States
-
Indiana UniversityOptonolTerminated
-
Jørgen Bjerggaard JensenActive, not recruiting
-
Croatian Cooperative Group for Clinical Research...Roche Pharma AGUnknownBreast Cancer | MetastasisCroatia
-
Prakash PandalaiRecruiting
-
University of Rome Tor VergataUniversity Of Perugia; University of L'AquilaCompletedBladder Cancer TNM Staging Primary Tumor (T) Ta | Bladder Cancer TNM Staging Primary Tumor (T) T1 | Bladder Cancer Transitional Cell GradeItaly